Loading...
On July 17, 2008, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it will not move forward with PAVE 100, a large phase IIB vaccine trial designed to test a DNA prime, recombinant adenovirus serotype 5 (Ad5) boost HIV vaccine candidate developed by the NIH Vaccine Research Center (VRC).
PAVE 100 was slated to begin last fall but was postponed after an Ad5-based HIV vaccine candidate developed by Merck failed to prevent HIV infection or to reduce viral loads following infection in a phase IIB trial known as the STEP study (AIDS Clin Care Oct 1 2007). Subsequent analyses showed that the incidence of HIV infection in the STEP study was higher in vaccine recipients than in placebo recipients in the subgroup of in…